Literature DB >> 26452492

Evaluation of Left to Right Shunts by the Pediatrician: How to Follow, When to Refer for Intervention?

I B Vijayalakshmi1.   

Abstract

Left to right shunts are the most common congenital heart defects which may cause increased pulmonary blood flow leading to dilatation of cardiac chambers, congestive heart failure, pulmonary artery hypertension and eventually Eisenmenger's syndrome. Many children are, however, referred late for correction making them either high risk for intervention or inoperable. The device closure of atrial septal defect, ventricular septal defect and patent ductus arteriosus can literally cure the patient for life, without a scar on the chest. Hence, it is important for every pediatrician to know how to follow and when to refer the patients with left to right shunts for either device closure or surgical intervention, so that the patient can lead a near normal life.

Entities:  

Keywords:  Atrial septal defect; Device closure; Heart failure; Patent ductus arteriosus; Ventricular septal defect

Mesh:

Year:  2015        PMID: 26452492     DOI: 10.1007/s12098-015-1861-9

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  17 in total

1.  The natural history of the ductus arteriosus in association with other congenital heart defects.

Authors:  D E Cassels; S Bharati; M Lev
Journal:  Perspect Biol Med       Date:  1975       Impact factor: 1.416

Review 2.  Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus?

Authors:  Arvind Sehgal; Patrick J McNamara
Journal:  Eur J Pediatr       Date:  2009-04-22       Impact factor: 3.183

3.  Transcatheter closure as an alternative and equivalent method to the surgical treatment of atrial septal defect in adults: comparison of early and late results.

Authors:  Elzbieta Suchon; Monika Pieculewicz; Wieslawa Tracz; Tadeusz Przewlocki; Jerzy Sadowski; Piotr Podolec
Journal:  Med Sci Monit       Date:  2009-12

4.  A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.

Authors:  B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

Review 5.  Consensus on timing of intervention for common congenital heart diseases: part I - acyanotic heart defects.

Authors:  P Syamasundar Rao
Journal:  Indian J Pediatr       Date:  2012-06-30       Impact factor: 1.967

6.  Atrial septal defects that present in infancy.

Authors:  L T Mahoney; S C Truesdell; T R Krzmarzick; R M Lauer
Journal:  Am J Dis Child       Date:  1986-11

7.  Predictive factors for spontaneous closure of atrial septal defects diagnosed in the first 3 months of life.

Authors:  D Radzik; A Davignon; N van Doesburg; A Fournier; T Marchand; G Ducharme
Journal:  J Am Coll Cardiol       Date:  1993-09       Impact factor: 24.094

8.  Long-term follow-up and quality of life after closure of ventricular septal defect in adults.

Authors:  Goris Bol Raap; Folkert J Meijboom; A Pieter Kappetein; Tjebbe W Galema; Singh-Chien Yap; Ad J J C Bogers
Journal:  Eur J Cardiothorac Surg       Date:  2007-06-12       Impact factor: 4.191

9.  Frequency of development of aortic cuspal prolapse and aortic regurgitation in patients with subaortic ventricular septal defect diagnosed at <1 year of age.

Authors:  Susan F Saleeb; David E Solowiejczyk; Julie S Glickstein; Rosalind Korsin; Welton M Gersony; Daphne T Hsu
Journal:  Am J Cardiol       Date:  2007-04-17       Impact factor: 2.778

10.  Natural history of ventricular septal defect. A study involving 790 cases.

Authors:  P Corone; F Doyon; S Gaudeau; F Guérin; P Vernant; H Ducam; C Rumeau-Rouquette; P Gaudeul
Journal:  Circulation       Date:  1977-06       Impact factor: 29.690

View more
  1 in total

1.  Editorial: What Does the Pediatrician Needs to Know About Heart Defects in Children?

Authors:  P Syamasundar Rao
Journal:  Indian J Pediatr       Date:  2015-09-14       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.